VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 4.61 Million USD | -7.77% |
| 2021 | 5 Million USD | -43.15% |
| 2020 | 8.8 Million USD | 14.04% |
| 2019 | 7.72 Million USD | 0.0% |
| 2014 | 5.82 Million USD | -7.98% |
| 2013 | 6.33 Million USD | 119874.5% |
| 2012 | 5280.00 USD | 0.0% |
| 2006 | 8.34 Million USD | 163.97% |
| 2005 | 3.16 Million USD | 25.83% |
| 2004 | 2.51 Million USD | -74.85% |
| 2003 | 9.99 Million USD | 4.61% |
| 2002 | 9.55 Million USD | 1.01% |
| 2001 | 9.45 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 4.59 Million USD | -0.4% |
| 2023 Q3 | 4.55 Million USD | -1.79% |
| 2023 Q2 | 4.63 Million USD | 0.89% |
| 2022 FY | 4.61 Million USD | -7.77% |
| 2022 Q4 | 4.61 Million USD | 3.9% |
| 2022 Q3 | 4.44 Million USD | 0.0% |
| 2021 Q3 | 5.48 Million USD | 0.0% |
| 2021 FY | 5 Million USD | -43.15% |
| 2020 FY | 8.8 Million USD | 14.04% |
| 2019 FY | 7.72 Million USD | 0.0% |
| 2015 Q1 | 5.89 Million USD | 1.12% |
| 2015 Q3 | 5.46 Million USD | -8.32% |
| 2015 Q2 | 5.95 Million USD | 1.07% |
| 2014 Q4 | 5.82 Million USD | -7.58% |
| 2014 FY | 5.82 Million USD | -7.98% |
| 2014 Q1 | 6.22 Million USD | -1.76% |
| 2014 Q2 | 6.74 Million USD | 8.31% |
| 2014 Q3 | 6.3 Million USD | -6.42% |
| 2013 Q4 | 6.33 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 6.33 Million USD | 119874.5% |
| 2012 FY | 5280.00 USD | 0.0% |
| 2007 Q3 | 5.65 Million USD | -3.45% |
| 2007 Q2 | 5.85 Million USD | 10.95% |
| 2007 Q1 | 5.27 Million USD | -36.77% |
| 2006 Q2 | 6.2 Million USD | 10.22% |
| 2006 FY | 8.34 Million USD | 163.97% |
| 2006 Q1 | 5.62 Million USD | 77.95% |
| 2006 Q4 | 8.34 Million USD | 37.09% |
| 2006 Q3 | 6.08 Million USD | -1.83% |
| 2005 Q4 | 3.16 Million USD | 3.37% |
| 2005 Q3 | 3.05 Million USD | 12.01% |
| 2005 Q2 | 2.73 Million USD | 9.83% |
| 2005 Q1 | 2.48 Million USD | -1.05% |
| 2005 FY | 3.16 Million USD | 25.83% |
| 2004 FY | 2.51 Million USD | -74.85% |
| 2004 Q4 | 2.51 Million USD | 3.67% |
| 2004 Q3 | 2.42 Million USD | -75.39% |
| 2004 Q2 | 9.84 Million USD | -2.87% |
| 2004 Q1 | 10.14 Million USD | 1.47% |
| 2003 Q2 | 9.52 Million USD | -0.52% |
| 2003 FY | 9.99 Million USD | 4.61% |
| 2003 Q4 | 9.99 Million USD | -1.93% |
| 2003 Q3 | 10.19 Million USD | 7.0% |
| 2003 Q1 | 9.57 Million USD | 0.2% |
| 2002 Q3 | 9.53 Million USD | -4.57% |
| 2002 Q2 | 9.99 Million USD | 2.7% |
| 2002 Q1 | 9.73 Million USD | 4.27% |
| 2002 FY | 9.55 Million USD | 1.01% |
| 2002 Q4 | 9.55 Million USD | 0.14% |
| 2001 Q2 | - USD | -100.0% |
| 2001 FY | 9.45 Million USD | 0.0% |
| 2001 Q3 | 280.83 Thousand USD | 0.0% |
| 2001 Q1 | 246.87 Thousand USD | 1.36% |
| 2001 Q4 | 9.33 Million USD | 3224.19% |
| 2000 Q4 | 243.55 Thousand USD | 1.31% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | 240.41 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -16730.551% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 51.224% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.629% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -470.865% |
| Rebus Holdings, Inc. | 5.24 Million USD | 11.921% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 92.176% |
| Qrons Inc. | 1.48 Million USD | -210.142% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -276.535% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.837% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -10230.063% |
| Skye Bioscience, Inc. | 14.07 Million USD | 67.19% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 91.338% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 51.815% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -995.227% |
| SQZ Biotechnologies Company | 50.03 Million USD | 90.773% |
| Intellipharmaceutics International Inc. | 12 Million USD | 61.552% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -19.881% |
| Mesoblast Limited | 188.44 Million USD | 97.55% |
| Marizyme, Inc. | 26.67 Million USD | 82.692% |
| Genus plc | 485 Million USD | 99.048% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 20.975% |
| Pharming Group N.V. | 244.07 Million USD | 98.108% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -129.693% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -83.487% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -21.503% |
| ContraFect Corporation | 32.53 Million USD | 85.807% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -133.034% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -20.626% |
| IMV Inc. | 37.93 Million USD | 87.828% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 60.799% |
| MultiCell Technologies, Inc. | 1617.67 USD | -285318.225% |
| ONE Bio Corp. | 27.49 Million USD | 83.208% |
| Accustem Sciences Inc. | 1.07 Million USD | -327.813% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.036% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -118.297% |
| Q BioMed Inc. | 8.13 Million USD | 43.229% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 94.433% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 10.278% |
| Biomind Labs Inc. | 1.49 Million USD | -208.093% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.111% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 48.938% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 74.912% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -222.006% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3149.323% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2195.752% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 19.644% |
| GB Sciences, Inc. | 5.41 Million USD | 14.775% |
| Alpha Cognition Inc. | 7.16 Million USD | 35.558% |
| HST Global, Inc. | 593.59 Thousand USD | -677.827% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -266.673% |
| Halberd Corporation | 728.71 Thousand USD | -533.595% |
| Enzolytics Inc. | 365.26 Million USD | 98.736% |
| Agentix Corp. | 2.51 Million USD | -83.909% |
| Resverlogix Corp. | 67.39 Million USD | 93.149% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -450.489% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.962% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -169.377% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 81.342% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 61.211% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -25.973% |
| AVAX Technologies, Inc. | 3.99 Million USD | -15.609% |
| Zenith Capital Corp. | 27.56 Thousand USD | -16647.524% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.652% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1834.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -23.641% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -578.157% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -70.271% |
| Kadimastem Ltd | 3.5 Million USD | -31.735% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -6798.542% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 90.814% |
| BioStem Technologies, Inc. | 15.9 Million USD | 70.97% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -893.573% |
| LadRx Corporation | 2.2 Million USD | -109.819% |
| Cell Source, Inc. | 15.8 Million USD | 70.79% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.4% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.4% |
| NovAccess Global Inc. | 7.86 Million USD | 41.263% |
| Affymax, Inc. | 8.87 Million USD | 47.953% |
| Itoco Inc. | 1.65 Million USD | -179.292% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -125.054% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 23.671% |
| Mobile Lads Corp. | 1.31 Million USD | -251.514% |
| CytoDyn Inc. | 127.89 Million USD | 96.39% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -10946.018% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -194.765% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 58.198% |
| SYBLEU INC | 681.41 Thousand USD | -577.581% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 24.333% |
| International Stem Cell Corporation | 5.27 Million USD | 12.505% |
| Bioxytran, Inc. | 3.24 Million USD | -42.087% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -637.785% |
| Cardax, Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 88.738% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 79.263% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -127.963% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 15.715% |
| Neutra Corp. | 973.52 Thousand USD | -374.267% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 84.087% |
| PureTech Health plc | 125.58 Million USD | 96.323% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -22.89% |
| IXICO plc | 1.9 Million USD | -142.969% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 77.509% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.531% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Cellectis S.A. | 249.36 Million USD | 98.148% |